Lessons from CTLA-4 deficiency and checkpoint inhibition

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

CTLA-4 is a crucial negative regulator of immune responses. Absence of CTLA-4 in mice causes autoimmunity and lethal multiorgan lymphocytic infiltration and tissue destruction. Recently, heterozygous CTLA4 or biallelic LRBA mutations leading to functional CTLA-4 deficiency and autoimmunity have been discovered. LRBA was identified as a novel regulator of steady-state CTLA-4 protein levels in Tregs and activated T cells. CTLA-4 deficiency due to checkpoint blockade cancer immunotherapy has also been found to lead to autoimmune reactions. Studies investigating the variable efficacy and adverse autoimmune responses to checkpoint therapy elucidated a role of the microbiota in promoting antitumor and autoreactive immune responses that are regulated by CTLA-4.

Original languageEnglish
Pages (from-to)14-19
Number of pages6
JournalCurrent Opinion in Immunology
Volume49
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Autoimmunity
Microbiota
Immunotherapy
T-Lymphocytes
Mutation
Neoplasms
Proteins
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Lessons from CTLA-4 deficiency and checkpoint inhibition. / Lo, Bernice; Abdel-Motal, Ussama M.

In: Current Opinion in Immunology, Vol. 49, 01.12.2017, p. 14-19.

Research output: Contribution to journalReview article

@article{3708d77b682243e49ac35050402636cb,
title = "Lessons from CTLA-4 deficiency and checkpoint inhibition",
abstract = "CTLA-4 is a crucial negative regulator of immune responses. Absence of CTLA-4 in mice causes autoimmunity and lethal multiorgan lymphocytic infiltration and tissue destruction. Recently, heterozygous CTLA4 or biallelic LRBA mutations leading to functional CTLA-4 deficiency and autoimmunity have been discovered. LRBA was identified as a novel regulator of steady-state CTLA-4 protein levels in Tregs and activated T cells. CTLA-4 deficiency due to checkpoint blockade cancer immunotherapy has also been found to lead to autoimmune reactions. Studies investigating the variable efficacy and adverse autoimmune responses to checkpoint therapy elucidated a role of the microbiota in promoting antitumor and autoreactive immune responses that are regulated by CTLA-4.",
author = "Bernice Lo and Abdel-Motal, {Ussama M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.coi.2017.07.014",
language = "English",
volume = "49",
pages = "14--19",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Lessons from CTLA-4 deficiency and checkpoint inhibition

AU - Lo, Bernice

AU - Abdel-Motal, Ussama M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - CTLA-4 is a crucial negative regulator of immune responses. Absence of CTLA-4 in mice causes autoimmunity and lethal multiorgan lymphocytic infiltration and tissue destruction. Recently, heterozygous CTLA4 or biallelic LRBA mutations leading to functional CTLA-4 deficiency and autoimmunity have been discovered. LRBA was identified as a novel regulator of steady-state CTLA-4 protein levels in Tregs and activated T cells. CTLA-4 deficiency due to checkpoint blockade cancer immunotherapy has also been found to lead to autoimmune reactions. Studies investigating the variable efficacy and adverse autoimmune responses to checkpoint therapy elucidated a role of the microbiota in promoting antitumor and autoreactive immune responses that are regulated by CTLA-4.

AB - CTLA-4 is a crucial negative regulator of immune responses. Absence of CTLA-4 in mice causes autoimmunity and lethal multiorgan lymphocytic infiltration and tissue destruction. Recently, heterozygous CTLA4 or biallelic LRBA mutations leading to functional CTLA-4 deficiency and autoimmunity have been discovered. LRBA was identified as a novel regulator of steady-state CTLA-4 protein levels in Tregs and activated T cells. CTLA-4 deficiency due to checkpoint blockade cancer immunotherapy has also been found to lead to autoimmune reactions. Studies investigating the variable efficacy and adverse autoimmune responses to checkpoint therapy elucidated a role of the microbiota in promoting antitumor and autoreactive immune responses that are regulated by CTLA-4.

UR - http://www.scopus.com/inward/record.url?scp=85027854031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027854031&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2017.07.014

DO - 10.1016/j.coi.2017.07.014

M3 - Review article

C2 - 28806575

AN - SCOPUS:85027854031

VL - 49

SP - 14

EP - 19

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -